Methylation-dependent Tissue Factor Suppression Contributes to the Reduced Malignancy of IDH1-mutant Gliomas

Purpose: Gliomas with isocitrate dehydrogenase 1 mutations (IDH1mut) are less aggressive than IDH1 wild-type (IDH1wt) gliomas and have global genomic hypermethylation. Yet it is unclear how specific hypermethylation events contribute to the IDH1mut phenotype. Previously, we showed that the gene encoding the procoagulant tissue factor (TF), F3, is among the most hypermethylated and downregulated genes in IDH1mut gliomas, correlating with greatly reduced thrombosis in patients with IDH1mut glioma. Because TF also increases the aggressiveness of many cancers, the current study explored the contribution of TF suppression to the reduced malignancy of IDH1mut gliomas. Experimental Design: TF expression was manipulated in patient-derived IDH1mut and IDH1wt glioma cells, followed by evaluation of in vitro and in vivo behavior and analyses of cell signaling pathways. Results: A demethylating agent, decitabine, increased F3 transcription and TF-dependent coagulative activity in IDH1mut cells, but not in IDH1wt cells. TF induction enhanced the proliferation, invasion, and colony formation of IDH1mut cells, and increased the intracranial engraftment of IDH1mut GBM164 from 0% to 100% (P = 0.0001). Conversely, TF knockdown doubled the median survival of mice engrafted with IDH1wt/EGFRvIIIamp GBM6, and caused complete regression of IDH1wt/EGFRamp GBM12 (P = 0.001). In vitro and in vivo effects were linked to activation of receptor tyrosine kinases (RTK) by TF through a Src-dependent intracellular pathway, even when extracellular RTK stimulation was blocked. TF stimulated invasion predominately through upregulation of β-catenin. Conclusions: These data show that TF suppression is a component of IDH1mut glioma behavior, and that it may therefore be an attractive target against IDH1wt gliomas.

[1]  L. Huang,et al.  Friend or foe—IDH1 mutations in glioma 10 years on , 2019, Carcinogenesis.

[2]  D. Scholtens,et al.  Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers , 2019, Scientific Reports.

[3]  M. Mikuła,et al.  IDH1/2 Mutations Predict Shorter Survival in Chondrosarcoma , 2018, Journal of Cancer.

[4]  James J. Morrow,et al.  Positively selected enhancer elements endow osteosarcoma cells with metastatic competence , 2017, Nature Medicine.

[5]  Pedro P. Rocha,et al.  Low-Grade Astrocytoma Mutations in IDH1, P53, and ATRX Cooperate to Block Differentiation of Human Neural Stem Cells via Repression of SOX2. , 2017, Cell reports.

[6]  Steven J. M. Jones,et al.  Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1 , 2017, Proceedings of the National Academy of Sciences.

[7]  D. Kondziolka,et al.  Mutant IDH1 and thrombosis in gliomas , 2016, Acta Neuropathologica.

[8]  A. Azmi,et al.  Tissue invasion and metastasis: Molecular, biological and clinical perspectives. , 2015, Seminars in cancer biology.

[9]  Darrell,et al.  Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. , 2015, The oncologist.

[10]  Steven J. M. Jones,et al.  Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.

[11]  L. Montermini,et al.  The contribution of tumor and host tissue factor expression to oncogene-driven gliomagenesis. , 2014, Biochemical and biophysical research communications.

[12]  R. Ammendola,et al.  Cell-Surface Receptors Transactivation Mediated by G Protein-Coupled Receptors , 2014, International journal of molecular sciences.

[13]  A. Iafrate,et al.  Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH-Mutant Gliomas , 2014, Clinical Cancer Research.

[14]  G. Bourque,et al.  Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations , 2014, Proceedings of the National Academy of Sciences.

[15]  M. Ross,et al.  Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2 , 2013, Nature Communications.

[16]  T. Mak,et al.  Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. , 2013, Cancer discovery.

[17]  T. Helleday,et al.  5-Aza-2′-deoxycytidine causes replication lesions that require Fanconi anemia-dependent homologous recombination for repair , 2013, Nucleic acids research.

[18]  C. Horbinski What do we know about IDH1/2 mutations so far, and how do we use it? , 2013, Acta Neuropathologica.

[19]  A. Vazquez,et al.  Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. , 2013, Cancer research.

[20]  Carsten Denkert,et al.  Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization , 2012, PloS one.

[21]  G. Nikkhah,et al.  Activation of canonical WNT/β-catenin signaling enhances in vitro motility of glioblastoma cells by activation of ZEB1 and other activators of epithelial-to-mesenchymal transition. , 2012, Cancer letters.

[22]  R. Pieper,et al.  Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency. , 2012, Cancer research.

[23]  Peter A. Jones Functions of DNA methylation: islands, start sites, gene bodies and beyond , 2012, Nature Reviews Genetics.

[24]  Z. Culig,et al.  Abstract 3350: Implications of the STAT6 pathway by interleukin-4 in prostate cancer , 2012 .

[25]  S. Berger,et al.  IDH mutation impairs histone demethylation and results in a block to cell differentiation , 2012, Nature.

[26]  R. Verhaak,et al.  Transformation by the R Enantiomer of 2-Hydroxyglutarate Linked to EglN Activation , 2012, Nature.

[27]  S. Weiss,et al.  An in vivo patient-derived model of endogenous IDH1-mutant glioma. , 2012, Neuro-oncology.

[28]  P. Reitsma,et al.  The relationship between tissue factor and cancer progression: insights from bench and bedside. , 2012, Blood.

[29]  W. Ruf,et al.  Tissue factor and cell signalling in cancer progression and thrombosis , 2011, Journal of thrombosis and haemostasis : JTH.

[30]  T. Shibata,et al.  Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation. , 2011, The American journal of pathology.

[31]  P. Liberski,et al.  Glioma cells showing IDH1 mutation cannot be propagated in standard cell culture conditions , 2011, British Journal of Cancer.

[32]  J. Rak,et al.  Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells. , 2010, Blood.

[33]  R. Wilson,et al.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.

[34]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[35]  Marc W. Kirschner,et al.  Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling , 2009, Nature.

[36]  E. Conway,et al.  Coagulation and innate immune responses: can we view them separately? , 2009, Blood.

[37]  Erwin G. Van Meir,et al.  Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. , 2009, Cancer research.

[38]  A. Guha,et al.  Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis. , 2008, Cancer research.

[39]  C. Bokemeyer,et al.  Platinum-based chemotherapy plus cetuximab in head and neck cancer. , 2008, The New England journal of medicine.

[40]  Keith D. Robertson,et al.  DNA Methylation Inhibitor 5-Aza-2′-Deoxycytidine Induces Reversible Genome-Wide DNA Damage That Is Distinctly Influenced by DNA Methyltransferases 1 and 3B , 2007, Molecular and Cellular Biology.

[41]  C. James,et al.  Use of an Orthotopic Xenograft Model for Assessing the Effect of Epidermal Growth Factor Receptor Amplification on Glioblastoma Radiation Response , 2006, Clinical Cancer Research.

[42]  C. James,et al.  Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. , 2005, Neuro-oncology.

[43]  H. Prydz,et al.  The epidermal growth factor receptor (EGFR) and proline rich tyrosine kinase 2 (PYK2) are involved in tissue factor dependent factor VIIa signalling in HaCaT cells , 2004, Thrombosis and Haemostasis.

[44]  S. Coughlin,et al.  Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[45]  N. Mackman,et al.  Complete sequence of the human tissue factor gene, a highly regulated cellular receptor that initiates the coagulation protease cascade. , 1989, Biochemistry.

[46]  H. Dvorak Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. , 1986, The New England journal of medicine.

[47]  R. Verhaak,et al.  GlioVis data portal for visualization and analysis of brain tumor expression datasets. , 2017, Neuro-oncology.

[48]  P. Reitsma,et al.  New fundamentals in hemostasis. , 2013, Physiological reviews.

[49]  J. Uhm IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012 .

[50]  Zhujun Wang,et al.  Prognostic significance of IDH1 mutations in acute myeloid leukemia: a meta-analysis. , 2012, American journal of blood research.

[51]  F. Ducray,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[52]  J. Geng,et al.  Tissue factor; from Morawitz to microparticles. , 2007, Transactions of the American Clinical and Climatological Association.